Embecta

Embecta Cash & Equivalents

The Cash & Short-Term Investments of Embecta (EMBC) as of Nov 12, 2026 is 225.50 M USD. In the previous year, Cash & Short-Term Investments was 267.50 M USD — a change of -15.70% (lower).

Cash & Equivalents

225.50 MUSD

YoY

-15.70%

Last updated:

Cash & Short-Term Investments of Embecta is 2025 225.50 M USD. Cash & Short-Term Investments of Embecta was 2024 267.50 M USD. It decreases by -15.70% lower compared to the previous year.

The Embecta Cash & Equivalents history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash & Equivalents
Date
Cash & Equivalents
Jan 1, 2022
330.90 M USD
Jan 1, 2023
326.50 M USD
Jan 1, 2024
267.50 M USD
Jan 1, 2025
225.50 M USD
The Embecta Cash & Equivalents history
YEARCash & EquivalentsYoY
225.50 MUSD-15.70%
267.50 MUSD-18.07%
326.50 MUSD-1.33%
330.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Cash & Short-Term Investments of Embecta is 225.50 M USD in 2025.

Cash & Short-Term Investments of Embecta changed from 267.50 M USD to 225.50 M USD, representing a -15.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Embecta since 2006 – with annual values, charts, and detailed analysis.

Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.

Cash & Short-Term Investments's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Embecta

All Key Metrics — Embecta